{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:02:24Z","timestamp":1792803744862,"version":"4.5.0"},"reference-count":104,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T00:00:00Z","timestamp":1757462400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Korea Institute of Radiological and Medical Sciences (KIRAMS), funded by Ministry of Science and ICT (MSIT), Republic of Korea","award":["50552-2025"],"award-info":[{"award-number":["50552-2025"]}],"id":[{"id":"https:\/\/ror.org\/00a8tg325","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Soonchunhyang University Research Fund","award":["50552-2025"],"award-info":[{"award-number":["50552-2025"]}],"id":[{"id":"https:\/\/ror.org\/03qjsrb10","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: The optimal treatment strategy for locally advanced unresectable pancreatic cancer (LAPC) is still investigated. Therefore, we evaluated the role of radiotherapy (RT) in the management of LAPC in the modern era. Methods: A systematic review was conducted following the Preferred Reporting Items for Systemic Review and Meta-Analyses guidelines. Eligible studies were about for LAPC treated with curative-intent modern RT techniques including intensity-modulated radiotherapy (IMRT), stereotactic body radiotherapy (SBRT), and particle beam therapy (PBT) until September 2024. Results: In total, 53 observational studies, encompassing 2548 patients (993 treated with IMRT, 998 with SBRT, and 557 with PBT), met the inclusion criteria. Concurrent chemoradiotherapy (CCRT) was implemented in 28 studies, including only 3 studies in the SBRT group. Elective nodal irradiation (ENI) was adopted in 22%. The pooled 2-year overall survival (OS) rate was 29% (95% confidence interval [CI], 25\u201334%) for all patients, with no significant differences among RT techniques: 28% (95% CI, 22\u201334%) for IMRT, 26% (95% CI, 19\u201334%) for SBRT, and 43% (95% CI, 28\u201357%) for PBT (p = 0.1121). The pooled rate of acute hematologic toxicity (HT) \u2265 grade 3 was 17% (95% CI, 9\u201326%), with significant differences among RT techniques: 23% (95% CI, 9\u201340%) for IMRT, 4% (95% CI, 0\u201311%) for SBRT, and 20% (95% CI, 6\u201337%) for PBT (p = 0.0181). In addition, CCRT (p = 0.0084) and ENI (p = 0.0145) significantly increased the risk of acute HT. Gastrointestinal toxicities rarely occurred. Conclusions: This systematic review and meta-analysis showed similar efficacy among modern RT techniques for LAPC management. Since almost all studies have single-arm design, and chemotherapy regimens have changed over time, conclusions must be drawn with caution. The use of modern RT techniques is individually selected according to clinical practice and resource availability.<\/jats:p>","DOI":"10.3390\/cancers17182959","type":"journal-article","created":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T08:43:54Z","timestamp":1757493834000},"page":"2959","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Radiotherapy for Locally Advanced Pancreatic Cancer in the Modern Era: A Systematic Review and Meta-Analysis"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0637-4110","authenticated-orcid":false,"given":"Sun Hyun","family":"Bae","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Soonchunhyang University College of Medicine, Bucheon 14584, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5279-3087","authenticated-orcid":false,"given":"Won Il","family":"Jang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Korea Institute of Radiological and Medical Sciences, Seoul 01812, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2009-7263","authenticated-orcid":false,"given":"Jeong Il","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hee Chul","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7293-7463","authenticated-orcid":false,"given":"Ji Eun","family":"Moon","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Soonchunhyang University College of Medicine, Bucheon 14584, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0364-682X","authenticated-orcid":false,"given":"Karin","family":"Haustermans","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University Hospitals Leuven, 3000 Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0320-559X","authenticated-orcid":false,"given":"Marta","family":"Scorsetti","sequence":"additional","affiliation":[{"name":"Radiotherapy and Radiosurgery Department, IRCCS Humanitas Research Hospital, Rozzano, 20089 Milan, Italy"},{"name":"Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, 20072 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8609-0008","authenticated-orcid":false,"given":"Morten","family":"H\u00f8yer","sequence":"additional","affiliation":[{"name":"Danish Center for Particle Therapy, Aarhus University Hospital, 8200 Aarhus, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mi Sook","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Korea Institute of Radiological and Medical Sciences, Seoul 01812, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,9,10]]},"reference":[{"key":"ref_1","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1053\/j.seminoncol.2007.05.007","article-title":"Locally advanced pancreatic cancer: A review","volume":"34","author":"Russo","year":"2007","journal-title":"Semin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1200\/JCO.2016.67.5561","article-title":"Locally Advanced, Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline","volume":"34","author":"Balaban","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.annonc.2023.08.009","article-title":"Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Conroy","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_5","unstructured":"National Comprehensive Cancer Network NCCN Guidelines: Pancreatic Adenocarcinoma. Available online: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/pancreatic.pdf."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1016\/S0140-6736(20)30974-0","article-title":"Pancreatic cancer","volume":"395","author":"Mizrahi","year":"2020","journal-title":"Lancet"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1200\/JCO.1985.3.3.373","article-title":"Treatment of locally unresectable cancer of the stomach and pancreas: A randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil\u2014An Eastern Cooperative Oncology Group study","volume":"3","author":"Klaassen","year":"1985","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Gastrointestinal Tumor Study Group (1988). Treatment of locally unresectable carcinoma of the pancreas: Comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. J. Natl. Cancer Inst., 80, 751\u2013755.","DOI":"10.1093\/jnci\/80.10.751"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1093\/annonc\/mdn281","article-title":"Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD\/SFRO study","volume":"19","author":"Chauffert","year":"2008","journal-title":"Ann. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"4105","DOI":"10.1200\/JCO.2011.34.8904","article-title":"Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: An Eastern Cooperative Oncology Group trial","volume":"29","author":"Loehrer","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1001\/jama.2016.4324","article-title":"Effect of Chemoradiotherapy vs. Chemotherapy on Survival in Patients with Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine with or without Erlotinib: The LAP07 Randomized Clinical Trial","volume":"315","author":"Hammel","year":"2016","journal-title":"JAMA"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e12260","DOI":"10.1097\/MD.0000000000012260","article-title":"Effects of chemoradiotherapy and chemotherapy on survival of patients with locally advanced pancreatic cancer: A meta-analysis of randomized controlled trials","volume":"97","author":"Wang","year":"2018","journal-title":"Medicine"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"101139","DOI":"10.1016\/j.tranon.2021.101139","article-title":"Survival outcome after stereotactic body radiotherapy for locally advanced and borderline resectable pancreatic cancer: A systematic review and meta-analysis","volume":"14","author":"Liu","year":"2021","journal-title":"Transl. Oncol."},{"key":"ref_14","first-page":"100738","article-title":"Stereotactic body radiotherapy for pancreatic cancer\u2014A systematic review of prospective data","volume":"45","author":"Shouman","year":"2024","journal-title":"Clin. Transl. Radiat. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"5690","DOI":"10.3390\/curroncol30060427","article-title":"Comparative Effectiveness of Chemotherapy Alone Versus Radiotherapy-Based Regimens in Locally Advanced Pancreatic Cancer: A Real-World Multicenter Analysis (PAULA-1)","volume":"30","author":"Arcelli","year":"2023","journal-title":"Curr. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S1470-2045(08)70098-6","article-title":"Evidence behind use of intensity-modulated radiotherapy: A systematic review of comparative clinical studies","volume":"9","author":"Veldeman","year":"2008","journal-title":"Lancet Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1002\/1878-0261.12677","article-title":"Particle therapy in Europe","volume":"14","author":"Grau","year":"2020","journal-title":"Mol. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur. J. Epidemiol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control. Clin. Trials"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"ref_22","first-page":"100778","article-title":"Hypofractionated radiotherapy concomitant to capecitabine after induction chemotherapy for advanced pancreatic adenocarcinoma","volume":"47","author":"Passoni","year":"2024","journal-title":"Clin. Transl. Radiat. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s13014-023-02288-3","article-title":"Impact of planning organ at risk volume margins and matching method on late gastrointestinal toxicity in moderately hypofractionated IMRT for locally advanced pancreatic ductal adenocarcinoma","volume":"18","author":"Ogawa","year":"2023","journal-title":"Radiat. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"468","DOI":"10.4149\/neo_2023_230409N193","article-title":"Chemotherapy versus chemoradiotherapy in borderline resectable and locally advanced pancreatic adenocarcinoma","volume":"70","author":"Argalacsova","year":"2023","journal-title":"Neoplasma"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Shi, Z., Yang, J., Kong, W., Qiu, X., Lu, C., Liu, J., Liu, B., and Du, J. (2022). Use of Nab-Paclitaxel Plus Gemcitabine Followed by Hypofractionated Tomotherapy with Simultaneous Integrated Boost in Patients with Locally Advanced Pancreatic Cancer. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.782730"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1097\/MPA.0000000000002065","article-title":"Phase I Trial of nab-Paclitaxel Administered Concurrently with Radiotherapy in Patients with Locally Advanced Inoperable Pancreatic Adenocarcinoma","volume":"51","author":"Roy","year":"2022","journal-title":"Pancreas"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1001\/jamaoncol.2021.0057","article-title":"Association of Ablative Radiation Therapy with Survival Among Patients with Inoperable Pancreatic Cancer","volume":"7","author":"Reyngold","year":"2021","journal-title":"JAMA Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.currproblcancer.2019.04.003","article-title":"Hypofractionated intensity-modulated radiotherapy in locally advanced unresectable pancreatic cancer: A pilot study","volume":"43","author":"Benevento","year":"2019","journal-title":"Curr. Probl. Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"474","DOI":"10.21037\/jgo.2019.01.25","article-title":"Dose escalated concurrent chemo-radiation in borderline resectable and locally advanced pancreatic cancers with tomotherapy based intensity modulated radiotherapy: A phase II study","volume":"10","author":"Lewis","year":"2019","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1200\/JCO.19.00730","article-title":"Dose Escalation Trial of the Wee1 Inhibitor Adavosertib (AZD1775) in Combination with Gemcitabine and Radiation for Patients with Locally Advanced Pancreatic Cancer","volume":"37","author":"Cuneo","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"200","DOI":"10.3857\/roj.2018.00073","article-title":"Effectiveness and feasibility of concurrent chemoradiotherapy using simultaneous integrated boost-intensity modulated radiotherapy with and without induction chemotherapy for locally advanced pancreatic cancer","volume":"36","author":"Oh","year":"2018","journal-title":"Radiat. Oncol. J."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s13014-018-1063-5","article-title":"Clinical evaluation of intensity-modulated radiotherapy for locally advanced pancreatic cancer","volume":"13","author":"Goto","year":"2018","journal-title":"Radiat. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1080\/0284186X.2017.1342863","article-title":"Stereotactic body radiation vs. intensity-modulated radiation for unresectable pancreatic cancer","volume":"56","author":"Park","year":"2017","journal-title":"Acta Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.adro.2017.02.004","article-title":"Dose escalation with an IMRT technique in 15 to 28 fractions is better tolerated than standard doses of 3DCRT for LAPC","volume":"2","author":"Colbert","year":"2017","journal-title":"Adv. Radiat. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13014-014-0312-5","article-title":"Intensity modulated radiotherapy for locally advanced and metastatic pancreatic cancer: A mono-institutional retrospective analysis","volume":"10","author":"Wang","year":"2015","journal-title":"Radiat. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s00280-014-2488-7","article-title":"Phase I dose escalation study of capecitabine and erlotinib concurrent with radiation in locally advanced pancreatic cancer","volume":"74","author":"Jiang","year":"2014","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.ijrobp.2014.02.024","article-title":"Phase 1 pharmacogenetic and pharmacodynamic study of sorafenib with concurrent radiation therapy and gemcitabine in locally advanced unresectable pancreatic cancer","volume":"89","author":"Chiorean","year":"2014","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/j.ijrobp.2012.02.051","article-title":"A phase I\/II trial of intensity modulated radiation (IMRT) dose escalation with concurrent fixed-dose rate gemcitabine (FDR-G) in patients with unresectable pancreatic cancer","volume":"84","author":"Schipper","year":"2012","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e595","DOI":"10.1016\/j.ijrobp.2011.09.035","article-title":"Intensity-modulated radiotherapy for pancreatic adenocarcinoma","volume":"82","author":"Abelson","year":"2012","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.ijrobp.2003.11.003","article-title":"Intensity-modulated radiotherapy in treatment of pancreatic and bile duct malignancies: Toxicity and clinical outcome","volume":"59","author":"Milano","year":"2004","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"109541","DOI":"10.1016\/j.radonc.2023.109541","article-title":"Feasibility, safety, and efficacy of stereotactic body radiotherapy combined with intradermal heat-killed mycobacterium obuense (IMM-101) vaccination for non-progressive locally advanced pancreatic cancer, after induction chemotherapy with (modified)FOLFIRINOX\u2014The LAPC-2 trial","volume":"183","author":"Latifi","year":"2023","journal-title":"Radiother. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ijrobp.2023.03.036","article-title":"Phase 1 Dose Escalation Study of SBRT Using 3 Fractions for Locally Advanced Pancreatic Cancer","volume":"117","author":"Reyngold","year":"2023","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_43","first-page":"e38255","article-title":"Stereotactic Body Radiotherapy as an Effective Treatment for Pancreatic Cancer","volume":"15","author":"Hurmuz","year":"2023","journal-title":"Cureus"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Doppenberg, D., Lagerwaard, F.J., van Dieren, S., Meijerink, M.R., van der Vliet, J.J., Besselink, M.G., van Tienhoven, G., Versteijne, E., Slotman, B.J., and Wilmink, J.W. (2023). Optimizing patient selection for stereotactic ablative radiotherapy in patients with locally advanced pancreatic cancer after initial chemotherapy\u2014A single center prospective cohort. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1149961"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"7073","DOI":"10.3390\/curroncol30070513","article-title":"Can STEreotactic Body Radiation Therapy (SBRT) Improve the Prognosis of Unresectable Locally Advanced Pancreatic Cancer? Long-Term Clinical Outcomes, Toxicity and Prognostic Factors on 142 Patients (STEP Study)","volume":"30","author":"Comito","year":"2023","journal-title":"Curr. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Lee, H.I., Kang, H.C., and Chie, E.K. (2022). Consolidatory ablative stereotactic body radiation therapy after induction chemotherapy for unresectable pancreatic cancer: A single center experience. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.974454"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Kaucic, H., Kosmina, D., Schwarz, D., Mack, A., Sobat, H., Cehobasic, A., Leipold, V., Andrasek, I., Avdicevic, A., and Mlinaric, M. (2022). Stereotactic Ablative Radiotherapy Using CALYPSO\u00ae Extracranial Tracking for Intrafractional Tumor Motion Management-A New Potential Local Treatment for Unresectable Locally Advanced Pancreatic Cancer? Results from a Retrospective Study. Cancers, 14.","DOI":"10.3390\/cancers14112688"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.2147\/CMAR.S368662","article-title":"Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer Using Optical Surface Management System\u2014AlignRT as an Optical Body Surface Motion Management in Deep Breath Hold Patients: Results from a Single-Arm Retrospective Study","volume":"14","author":"Kaucic","year":"2022","journal-title":"Cancer Manag. Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.radonc.2021.07.009","article-title":"Stereotactic body radiation therapy with sequential S-1 for patients with locally advanced pancreatic cancer and poor performance status: An open-label, single-arm, phase 2 trial","volume":"162","author":"Zhu","year":"2021","journal-title":"Radiother. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.radonc.2020.11.006","article-title":"A phase II study of stereotactic radiotherapy after FOLFIRINOX for locally advanced pancreatic cancer (LAPC-1 trial): Long-term outcome","volume":"155","author":"Teriaca","year":"2021","journal-title":"Radiother. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"6736","DOI":"10.1002\/cam4.4214","article-title":"Phase I study of dose-escalated stereotactic body radiation therapy for locally advanced pancreatic head cancers: Initial clinical results","volume":"10","author":"Qing","year":"2021","journal-title":"Cancer Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"17588359211045860","DOI":"10.1177\/17588359211045860","article-title":"Isotoxic high-dose stereotactic body radiotherapy integrated in a total multimodal neoadjuvant strategy for the treatment of localized pancreatic ductal adenocarcinoma","volume":"13","author":"Bouchart","year":"2021","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Jung, J., Yoon, S.M., Park, J.H., Seo, D.W., Lee, S.S., Kim, M.H., Lee, S.K., Park, D.H., Song, T.J., and Ryoo, B.Y. (2019). Stereotactic body radiation therapy for locally advanced pancreatic cancer. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0214970"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.prro.2017.10.001","article-title":"Results of a prospective phase 2 clinical trial of induction gemcitabine\/capecitabine followed by stereotactic ablative radiation therapy in borderline resectable or locally advanced pancreatic adenocarcinoma","volume":"8","author":"Quan","year":"2018","journal-title":"Pract. Radiat. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.dld.2017.12.013","article-title":"Stereotactic body radiotherapy (SBRT) for patients with locally advanced pancreatic cancer: A single center experience","volume":"50","author":"Jumeau","year":"2018","journal-title":"Dig. Liver Dis."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"20170563","DOI":"10.1259\/bjr.20170563","article-title":"MRI guided stereotactic radiotherapy for locally advanced pancreatic cancer","volume":"91","author":"Heerkens","year":"2018","journal-title":"Br. J. Radiol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"979","DOI":"10.3109\/0284186X.2015.1004367","article-title":"Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma","volume":"54","author":"Mellon","year":"2015","journal-title":"Acta Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1002\/cncr.29161","article-title":"Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma","volume":"121","author":"Herman","year":"2015","journal-title":"Cancer"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/1748-717X-8-44","article-title":"Stereotactic body radiation therapy with concurrent full-dose gemcitabine for locally advanced pancreatic cancer: A pilot trial demonstrating safety","volume":"8","author":"Gurka","year":"2013","journal-title":"Radiat. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ijrobp.2010.05.006","article-title":"Single-fraction stereotactic body radiation therapy and sequential gemcitabine for the treatment of locally advanced pancreatic cancer","volume":"81","author":"Schellenberg","year":"2011","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"e615","DOI":"10.1016\/j.ijrobp.2011.04.045","article-title":"Induction gemcitabine and stereotactic body radiotherapy for locally advanced nonmetastatic pancreas cancer","volume":"81","author":"Mahadevan","year":"2011","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"802","DOI":"10.5732\/cjc.010.10112","article-title":"Preliminary efficacy of CyberKnife radiosurgery for locally advanced pancreatic cancer","volume":"29","author":"Shen","year":"2010","journal-title":"Chin. J. Cancer"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.ijrobp.2009.08.046","article-title":"Stereotactic body radiotherapy and gemcitabine for locally advanced pancreatic cancer","volume":"78","author":"Mahadevan","year":"2010","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.ijrobp.2008.01.051","article-title":"Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer","volume":"72","author":"Schellenberg","year":"2008","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Okamoto, M., Shiba, S., Kobayashi, D., Miyasaka, Y., Okazaki, S., Shibuya, K., and Ohno, T. (2023). Carbon-Ion Radiotherapy Combined with Concurrent Chemotherapy for Locally Advanced Pancreatic Cancer: A Retrospective Case Series Analysis. Cancers, 15.","DOI":"10.3390\/cancers15102857"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1007\/s00066-023-02106-5","article-title":"Treatment of primary or recurrent non-resectable pancreatic cancer with proton beam irradiation combined with gemcitabine-based chemotherapy","volume":"199","author":"Lautenschlaeger","year":"2023","journal-title":"Strahlenther. Onkol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s13014-023-02301-9","article-title":"Proton radiotherapy as a treatment strategy to increase survival in locally advanced pancreatic cancer in the body and tail: A retrospective study","volume":"18","author":"Ami","year":"2023","journal-title":"Radiat. Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.pan.2020.01.010","article-title":"Proton and carbon ion radiation therapy for locally advanced pancreatic cancer: A phase I dose escalation study","volume":"20","author":"Yu","year":"2020","journal-title":"Pancreatology"},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Kim, T.H., Lee, W.J., Woo, S.M., Oh, E.S., Youn, S.H., Jang, H.Y., Han, S.S., Park, S.J., Suh, Y.G., and Moon, S.H. (2020). Efficacy and feasibility of proton beam radiotherapy using the simultaneous integrated boost technique for locally advanced pancreatic cancer. Sci. Rep., 10.","DOI":"10.1038\/s41598-020-78875-1"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.radonc.2019.03.012","article-title":"Concurrent chemoradiotherapy using proton beams for unresectable locally advanced pancreatic cancer","volume":"136","author":"Hiroshima","year":"2019","journal-title":"Radiother. Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/j.ijrobp.2018.04.057","article-title":"Multi-institutional Study of Carbon-ion Radiotherapy for Locally Advanced Pancreatic Cancer: Japan Carbon-ion Radiation Oncology Study Group (J-CROS) Study 1403 Pancreas","volume":"101","author":"Kawashiro","year":"2018","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.pan.2017.07.191","article-title":"Comparison of proton beam radiotherapy and hyper-fractionated accelerated chemoradiotherapy for locally advanced pancreatic cancer","volume":"17","author":"Maemura","year":"2017","journal-title":"Pancreatology"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.ijrobp.2015.12.362","article-title":"Carbon Ion Radiation Therapy With Concurrent Gemcitabine for Patients With Locally Advanced Pancreatic Cancer","volume":"95","author":"Shinoto","year":"2016","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"692","DOI":"10.14338\/IJPT.14-00006.1","article-title":"ProtonTherapyandConcomitant CapecitabineforNon-Metastatic UnresectablePancreatic Adenocarcinoma","volume":"1","author":"Sachsman","year":"2014","journal-title":"Int. J. Part. Ther."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.3747\/co.23.2771","article-title":"Dosimetric and clinical toxicity comparison of critical organ preservation with three-dimensional conformal radiotherapy, intensity-modulated radiotherapy, and RapidArc for the treatment of locally advanced cancer of the pancreatic head","volume":"23","author":"Jin","year":"2016","journal-title":"Curr. Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.radonc.2014.11.043","article-title":"Comparison of toxicity after IMRT and 3D-conformal radiotherapy for patients with pancreatic cancer\u2014A systematic review","volume":"114","author":"Bittner","year":"2015","journal-title":"Radiother. Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"4","DOI":"10.21037\/tro.2018.07.06","article-title":"Effectiveness and acute toxicity of intensity-modulated radiotherapy versus three-dimensional conformal radiotherapy in pancreatic cancer: A systematic review and a meta-analy","volume":"2","author":"Chang","year":"2018","journal-title":"Ther. Radiol. Oncol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"e7434","DOI":"10.1002\/cam4.7434","article-title":"Escalated-dose radiotherapy for unresected locally advanced pancreatic cancer: Patterns of care and survival in the United States","volume":"13","author":"Shi","year":"2024","journal-title":"Cancer Med."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Burkon, P., Trna, J., Slavik, M., Nemecek, R., Kazda, T., Pospisil, P., Dastych, M., Eid, M., Novotny, I., and Prochazka, T. (2022). Stereotactic Body Radiotherapy (SBRT) of Pancreatic Cancer-A Critical Review and Practical Consideration. Biomedicines, 10.","DOI":"10.3390\/biomedicines10102480"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1002\/cncr.24059","article-title":"Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas","volume":"115","author":"Chang","year":"2009","journal-title":"Cancer"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.radonc.2004.12.022","article-title":"Phase-II study on stereotactic radiotherapy of locally advanced pancreatic carcinoma","volume":"76","author":"Hoyer","year":"2005","journal-title":"Radiother. Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.ijrobp.2024.10.026","article-title":"NRG Oncology International Consensus Contouring Atlas on Target Volumes and Dosing Strategies for Dose-Escalated Pancreatic Cancer Radiotherapy","volume":"121","author":"Sanford","year":"2024","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1002\/cncr.32756","article-title":"Conventionally fractionated radiation therapy versus stereotactic body radiation therapy for locally advanced pancreatic cancer (CRiSP): An international systematic review and meta-analysis","volume":"126","author":"Tchelebi","year":"2020","journal-title":"Cancer"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"4158","DOI":"10.1002\/cncr.30856","article-title":"Stereotactic body radiotherapy for unresected pancreatic cancer: A nationwide review","volume":"123","author":"Eskander","year":"2017","journal-title":"Cancer"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.bbcan.2017.02.003","article-title":"Biological determinants of radioresistance and their remediation in pancreatic cancer","volume":"1868","author":"Seshacharyulu","year":"2017","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Mohamad, O., Sishc, B.J., Saha, J., Pompos, A., Rahimi, A., Story, M.D., Davis, A.J., and Kim, D.W.N. (2017). Carbon Ion Radiotherapy: A Review of Clinical Experiences and Preclinical Research, with an Emphasis on DNA Damage\/Repair. Cancers, 9.","DOI":"10.3390\/cancers9060066"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"166","DOI":"10.21037\/jgo.2019.03.02","article-title":"Proton beam radiotherapy for pancreas cancer","volume":"11","author":"Rutenberg","year":"2020","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"286","DOI":"10.17998\/jlc.2024.06.26","article-title":"Recent update of proton beam therapy for hepatocellular carcinoma: A systematic review and meta-analysis","volume":"24","author":"Bae","year":"2024","journal-title":"J. Liver Cancer"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.clon.2014.06.002","article-title":"Locally advanced pancreatic cancer: The role of definitive chemoradiotherapy","volume":"26","author":"Huguet","year":"2014","journal-title":"Clin. Oncol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1200\/JCO.2006.07.5663","article-title":"Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies","volume":"25","author":"Huguet","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/cncr.22735","article-title":"Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy","volume":"110","author":"Krishnan","year":"2007","journal-title":"Cancer"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"3816","DOI":"10.1002\/cncr.30780","article-title":"Multiagent induction chemotherapy followed by chemoradiation is associated with improved survival in locally advanced pancreatic cancer","volume":"123","author":"Torgeson","year":"2017","journal-title":"Cancer"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1001\/jamasurg.2019.2277","article-title":"Outcomes of Primary Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma","volume":"154","author":"Maggino","year":"2019","journal-title":"JAMA Surg."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"e159","DOI":"10.1016\/j.lpm.2019.02.025","article-title":"Chemotherapy for pancreatic cancer","volume":"48","author":"Springfeld","year":"2019","journal-title":"Presse Med."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41575-023-00856-2","article-title":"Preoperative chemotherapy, radiotherapy and surgical decision-making in patients with borderline resectable and locally advanced pancreatic cancer","volume":"21","author":"Stoop","year":"2024","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00066-003-0976-5","article-title":"The impact of gross tumor volume (GTV) and clinical target volume (CTV) definition on the total accuracy in radiotherapy theoretical aspects and practical experiences","volume":"179","author":"Weiss","year":"2003","journal-title":"Strahlenther. Onkol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.ijrobp.2012.01.022","article-title":"Radiation Therapy Oncology Group consensus panel guidelines for the delineation of the clinical target volume in the postoperative treatment of pancreatic head cancer","volume":"83","author":"Goodman","year":"2012","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.ijrobp.2006.12.053","article-title":"Full-dose gemcitabine and concurrent radiotherapy for unresectable pancreatic cancer","volume":"68","author":"Murphy","year":"2007","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.radonc.2020.07.052","article-title":"ESTRO ACROP guidelines for target volume definition in pancreatic cancer","volume":"154","author":"Brunner","year":"2021","journal-title":"Radiother. Oncol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.prro.2019.06.016","article-title":"Radiation Therapy for Pancreatic Cancer: Executive Summary of an ASTRO Clinical Practice Guideline","volume":"9","author":"Palta","year":"2019","journal-title":"Pract. Radiat. Oncol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ije\/28.1.1","article-title":"Traditional reviews, meta-analyses and pooled analyses in epidemiology","volume":"28","author":"Blettner","year":"1999","journal-title":"Int. J. Epidemiol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Ervin","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_104","first-page":"100797","article-title":"Treatment planning for MR-guided SBRT of pancreatic tumors on a 1.5 T MR-Linac: A global consensus protocol","volume":"47","author":"Grimbergen","year":"2024","journal-title":"Clin. Transl. Radiat. Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/18\/2959\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:43:02Z","timestamp":1760035382000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/18\/2959"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,10]]},"references-count":104,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["cancers17182959"],"URL":"https:\/\/doi.org\/10.3390\/cancers17182959","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,10]]}}}